SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

NCT04050085 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Refractory Pancreatic Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions

BIOLOGICAL: Nivolumab
RADIATION: Radiation Therapy
DRUG: TLR9 Agonist SD-101

Sponsor

University of California, Davis

Collaborators

[object Object]
[object Object]
[object Object]